The White House says the Trump Administration's Most-Favored-Nation (MFN) drug pricing policy framework to address the major differences in drug prices and contributions to the pharmaceutical innovation enterprise across developed countries is expected to generate $529 billion in domestic savings in the next 10 years across all markets.
The Trump Administration has so far reached voluntary MFN pricing agreements with 17 of the largest pharmaceutical manufacturers in the world to lower prescription drug prices that Americans pay for some of the world's most innovative drugs, in line with the lowest prices paid by other developed nations, known as the most-favored-nation, or MFN, price.
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com